Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

BACKGROUND: Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve men with mCRPC), abiraterone acetate plus prednisone (AA) significantly improved radiographic progression-free survival...

詳細記述

保存先:
書誌詳細
出版年:Eur Urol
主要な著者: de Bono, Johann S., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric J., Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary B., Ryan, Charles J., Flaig, Thomas W.
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5609503/
https://ncbi.nlm.nih.gov/pubmed/27402060
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2016.06.033
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料